A retrospective 15‐year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|4|379-392

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.4, 2015-02, pp. : 379-392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The corrected donor age for hepatitis C virus–infected liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 8, 2015-08 ,pp. : 1022-1030

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infectious complications after liver transplantation in human immunodeficiency virus‐infected recipients

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 17, Iss. 5, 2015-10 ,pp. : 662-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infectious complications after liver transplantation in human immunodeficiency virus‐infected recipients

By  

TRANSPLANT INFECTIOUS DISEASE (ELECTRONIC), Vol. 1398-2273, Iss. 5, 2015-10 ,pp. : 662-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 6, 2015-06 ,pp. : 823-830

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 2, 2015-02 ,pp. : 272-274

John Wiley & Sons Inc

Access to resources Recommend Favorite